EPCORE FL-1 was a global, open-label, randomized phase 3 study comparing the combination of epcoritamab + lenalidomide + rituximab (R2) versus R2 alone in patients with relapsed or refractory follicular lymphoma after at least one line of chemoimmunotherapy.[1] At a median follow-up of 14.8 months, the combination with epcoritamab achieved an overall response rate of 95% (95% CI 92–97) versus 79% (74–84) in the R2 group (p<0.0001).[1] Progression-free survival was significantly longer with the addition of epcoritamab, with a hazard ratio of 0.21 (95% CI 0.14–0.31; p<0.0001); estimated 16-month progression-free survival was 85.5% vs 40.2% in favor of epcoritamab + R2.[1] There were more grade 3 or higher adverse events in the epcoritamab group than with R2 alone, but no new safety signals were noted and the adverse event profile was consistent with the known properties of the individual drugs.[1] According to the authors, adverse events were manageable.[1] Based on these results, the authors state that the combination of epcoritamab + R2 represents a new standard of care in the second and subsequent lines of treatment for follicular lymphoma.[1]